Brown Advisory Inc. raised its holdings in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 16.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,643,599 shares of the medical research company's stock after buying an additional 1,397,397 shares during the period. Brown Advisory Inc. owned about 7.57% of NeoGenomics worth $156,033,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in NEO. Quadrant Capital Group LLC increased its stake in shares of NeoGenomics by 22.0% during the fourth quarter. Quadrant Capital Group LLC now owns 4,900 shares of the medical research company's stock worth $79,000 after purchasing an additional 883 shares during the period. Mitsubishi UFJ Asset Management UK Ltd. lifted its holdings in shares of NeoGenomics by 17.1% during the fourth quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 48,000 shares of the medical research company's stock worth $777,000 after buying an additional 7,000 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of NeoGenomics by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,006,523 shares of the medical research company's stock valued at $48,650,000 after acquiring an additional 18,603 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of NeoGenomics by 4.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,046,565 shares of the medical research company's stock valued at $16,933,000 after acquiring an additional 41,794 shares in the last quarter. Finally, Lisanti Capital Growth LLC bought a new position in NeoGenomics during the fourth quarter worth about $3,445,000. 98.50% of the stock is owned by institutional investors and hedge funds.
NeoGenomics Stock Performance
Shares of NASDAQ NEO traded down $0.19 during midday trading on Friday, hitting $14.80. The company's stock had a trading volume of 639,983 shares, compared to its average volume of 894,617. The stock has a fifty day moving average price of $14.82 and a 200 day moving average price of $16.06. The firm has a market capitalization of $1.89 billion, a price-to-earnings ratio of -22.42 and a beta of 1.12. NeoGenomics, Inc. has a one year low of $11.03 and a one year high of $21.22. The company has a current ratio of 7.48, a quick ratio of 7.22 and a debt-to-equity ratio of 0.58.
NeoGenomics (NASDAQ:NEO - Get Free Report) last issued its quarterly earnings data on Tuesday, February 20th. The medical research company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.05. NeoGenomics had a negative net margin of 13.79% and a negative return on equity of 3.54%. The company had revenue of $155.55 million during the quarter, compared to analysts' expectations of $152.90 million. On average, research analysts forecast that NeoGenomics, Inc. will post -0.21 EPS for the current fiscal year.
Analyst Ratings Changes
A number of analysts have recently weighed in on NEO shares. William Blair reaffirmed an "outperform" rating on shares of NeoGenomics in a report on Wednesday, February 21st. Needham & Company LLC decreased their price target on NeoGenomics from $24.00 to $19.00 and set a "buy" rating on the stock in a research note on Tuesday, April 30th. Benchmark restated a "buy" rating and set a $18.00 price objective on shares of NeoGenomics in a research report on Wednesday, May 1st. Piper Sandler lifted their target price on NeoGenomics from $18.00 to $20.00 and gave the company an "overweight" rating in a research report on Monday, February 26th. Finally, Craig Hallum assumed coverage on shares of NeoGenomics in a report on Wednesday, May 1st. They issued a "buy" rating and a $26.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, NeoGenomics has an average rating of "Moderate Buy" and a consensus target price of $19.78.
Read Our Latest Research Report on NEO
NeoGenomics Profile
(
Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
